Previous close | 501.00 |
Open | 499.90 |
Bid | 504.20 x 0 |
Ask | 506.60 x 0 |
Day's range | 499.90 - 510.60 |
52-week range | 354.00 - 510.60 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.
McKesson Corporation (NYSE:MCK) Q4 2024 Earnings Call Transcript May 7, 2024 McKesson Corporation misses on earnings expectations. Reported EPS is $6.18 EPS, expectations were $6.36. McKesson Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Please stand by. Welcome to […]
Discover how McKesson's strategic initiatives and robust financial performance are shaping its industry leadership in Q4 2024.